Advances in non-covalent BTK inhibitors for CLL: BRUIN study update

Pirtobrutinib Non-Covalent BTK Inhibitor for Chronic Lymphocytic Leukemia (CLL) - BRUIN StudyПодробнее

Current state of the field: non-covalent BTK inhibitors for CLLПодробнее

Advances in BTK and BCL2 inhibitors for CLLПодробнее

Updated results of Phase I/II BRUIN study: pirtobrutinib in covalent BTK inhibitor pretreated MCLПодробнее

A retrospective study of outcomes with ven-based treatment in cBTKi-treated, chemotherapy-naïve CLLПодробнее

Update on the Phase I/II BRUIN studyПодробнее

Non-covalent vs covalent BTK inhibitors in CLLПодробнее

Updates on non-covalent BTK inhibitors and their place in CLL treatmentПодробнее

BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLLПодробнее

BELLWAVE-001: nemtabrutinib in patients with R/R CLL/SLLПодробнее

Customizing Care in CLL With BTK InhibitorsПодробнее

Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Context and Impact of New DataПодробнее

Considering the sequencing of covalent and non-covalent BTK inhibitors in CLLПодробнее

Progress With BTK Inhibitors: A Journey Through the Mechanisms of Covalent and Noncovalent OptionsПодробнее

Updates in CLL: Data and Recommendations for Using BTK InhibitorsПодробнее

Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLLПодробнее

Phase I/II BRUIN study: pirtobrutinib in patients intolerant to a covalent BTK inhibitorПодробнее

Sequencing of BTK inhibitors in CLLПодробнее

APPlexus Hot Topics 2024: Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCLПодробнее